Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros

Base de dados
Tipo de documento
Intervalo de ano de publicação
1.
BMC Cell Biol ; 14: 33, 2013 Aug 06.
Artigo em Inglês | MEDLINE | ID: mdl-23919615

RESUMO

BACKGROUND: The transcription factor E2F4 controls proliferation of normal and cancerous intestinal epithelial cells. E2F4 localization in normal human intestinal epithelial cells (HIEC) is cell cycle-dependent, being cytoplasmic in quiescent differentiated cells but nuclear in proliferative cells. However, the intracellular signaling mechanisms regulating such E2F4 localization remain unknown. RESULTS: Treatment of quiescent HIEC with serum induced ERK1/2 activation, E2F4 phosphorylation, E2F4 nuclear translocation and G1/S phase transition while inhibition of MEK/ERK signaling by U0126 prevented these events. Stimulation of HIEC with epidermal growth factor (EGF) also led to the activation of ERK1/2 but, in contrast to serum or lysophosphatidic acid (LPA), EGF failed to induce E2F4 phosphorylation, E2F4 nuclear translocation and G1/S phase transition. Furthermore, Akt and GSK3ß phosphorylation levels were markedly enhanced in serum- or LPA-stimulated HIEC but not by EGF. Importantly, E2F4 phosphorylation, E2F4 nuclear translocation and G1/S phase transition were all observed in response to EGF when GSK3 activity was concomitantly inhibited by SB216763. Finally, E2F4 was found to be overexpressed, phosphorylated and nuclear localized in epithelial cells from human colorectal adenomas exhibiting mutations in APC and KRAS or BRAF genes, known to deregulate GSK3/ß-catenin and MEK/ERK signaling, respectively. CONCLUSIONS: The present results indicate that MEK/ERK activation and GSK3 inhibition are both required for E2F4 phosphorylation as well as its nuclear translocation and S phase entry in HIEC. This finding suggests that dysregulated E2F4 nuclear localization may be an instigating event leading to hyperproliferation and hence, of tumor initiation and promotion in the colon and rectum.


Assuntos
Proliferação de Células/efeitos dos fármacos , Fator de Transcrição E2F4/efeitos dos fármacos , Fator de Transcrição E2F4/metabolismo , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Sistema de Sinalização das MAP Quinases/fisiologia , Mitógenos/farmacologia , Transcrição Gênica/efeitos dos fármacos , Adenoma/metabolismo , Adenoma/patologia , Butadienos/farmacologia , Ciclo Celular/efeitos dos fármacos , Ciclo Celular/fisiologia , Linhagem Celular , Células Cultivadas , Neoplasias Colorretais/metabolismo , Neoplasias Colorretais/patologia , Fator de Transcrição E2F4/genética , Inibidores Enzimáticos/farmacologia , Fator de Crescimento Epidérmico/farmacologia , Quinase 3 da Glicogênio Sintase/antagonistas & inibidores , Quinase 3 da Glicogênio Sintase/efeitos dos fármacos , Humanos , Mucosa Intestinal/efeitos dos fármacos , Lisofosfolipídeos/farmacologia , Sistema de Sinalização das MAP Quinases/efeitos dos fármacos , Nitrilas/farmacologia , Fosforilação/efeitos dos fármacos , Fosforilação/fisiologia , Transcrição Gênica/fisiologia
2.
Medicine (Baltimore) ; 97(4): e9653, 2018 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-29369181

RESUMO

Dexamethasone (DEX) could induce low birth weight of infant, and low birth weight has close associations with glucocorticoid levels, insulin resistance, hypertension, and metabolic syndrome in adulthood. This study was designed to reveal the action mechanisms of DEX on the birth weight of infant.Using quantitative real-time polymerase chain reaction (qRT-PCR), trophoblast cells of human placenta were identified and the optimum treatment time of DEX were determined. Trophoblast cells were treated by DEX (DEX group) or ethanol (control group) (each group had 3 samples), and then were performed with RNA-sequencing. Afterward, the differentially expressed genes (DEGs) were identified by R package, and their potential functions were successively enriched using DAVID database and Enrichr method. Followed by protein-protein interaction (PPI) network was constructed using Cytoscape software. Using Enrichr method and TargetScan software, the transcription factors (TFs) and micorRNAs (miRNAs) targeted the DEGs separately were predicted. Based on MsigDB database, gene set enrichment analysis (GSEA) was performed.There were 391 DEGs screened from the DEX group. Upregulated SRR and potassium voltage-gated channel subfamily J member 4 (KCNJ4) and downregulated GALNT1 separately were enriched in PDZ (an acronym of PSD-95, Dlg, and ZO-1) domain binding and Mucin type O-glycan biosynthesis. In the PPI network, CDK2 and CDK4 had higher degrees. TFs ATF2 and E2F4 and miRNA miR-16 were predicted for the DEGs. Moreover, qRT-PCR analysis confirmed that SRR and KCNJ4 were significantly upregulated.These genes might affect the roles of DEX in the birth weight of infant, and might be promising therapeutic targets for reducing the side effects of DEX.


Assuntos
Peso ao Nascer/genética , Dexametasona/efeitos adversos , Glucocorticoides/efeitos adversos , Análise de Sequência de RNA , Trofoblastos/efeitos dos fármacos , Fator 2 Ativador da Transcrição/efeitos dos fármacos , Peso ao Nascer/efeitos dos fármacos , Quinase 2 Dependente de Ciclina/efeitos dos fármacos , Quinase 4 Dependente de Ciclina/efeitos dos fármacos , Fator de Transcrição E2F4/efeitos dos fármacos , Feminino , Humanos , Recém-Nascido , MicroRNAs/efeitos dos fármacos , N-Acetilgalactosaminiltransferases/efeitos dos fármacos , Placenta/citologia , Canais de Potássio Corretores do Fluxo de Internalização/efeitos dos fármacos , Gravidez , Reação em Cadeia da Polimerase em Tempo Real , Polipeptídeo N-Acetilgalactosaminiltransferase
3.
Mol Cell Biol ; 30(2): 524-36, 2010 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19917728

RESUMO

The E2F transcription factors have emerged as critical apoptotic effectors. Herein we report that the E2F family member E2F3a can be induced by DNA damage through transcriptional and posttranslational mechanisms. We demonstrate that the posttranslational induction of human E2F3a is dependent on the checkpoint kinases. Moreover, we show that human E2F3a is a substrate for the checkpoint kinases (chk kinases) and that mutation of the chk phosphorylation site eliminates the DNA damage inducibility of the protein. Furthermore, we demonstrate that E2F1 and E2F2 are transcriptionally induced by DNA damage in an E2f3-dependent manner. Finally, using both in vitro and in vivo approaches, we establish that E2f3 is required for DNA damage-induced apoptosis. Thus, our data reveal the novel ability of E2f3 to function as a master regulator of the DNA damage response.


Assuntos
Apoptose , Sistema Nervoso Central/metabolismo , Dano ao DNA , Fator de Transcrição E2F3/metabolismo , Proteínas Quinases/metabolismo , Animais , Antibióticos Antineoplásicos/farmacologia , Antineoplásicos Fitogênicos/farmacologia , Linhagem Celular , Linhagem Celular Tumoral , Sistema Nervoso Central/patologia , Sistema Nervoso Central/efeitos da radiação , Quinase 1 do Ponto de Checagem , Doxorrubicina/farmacologia , Fator de Transcrição E2F1/efeitos dos fármacos , Fator de Transcrição E2F1/metabolismo , Fator de Transcrição E2F2/efeitos dos fármacos , Fator de Transcrição E2F2/metabolismo , Fator de Transcrição E2F3/agonistas , Fator de Transcrição E2F4/efeitos dos fármacos , Fator de Transcrição E2F4/metabolismo , Fator de Transcrição E2F5/efeitos dos fármacos , Fator de Transcrição E2F5/metabolismo , Etoposídeo/farmacologia , Humanos , Camundongos , Fosforilação/efeitos dos fármacos , Fosforilação/fisiologia , RNA Interferente Pequeno/metabolismo , Irradiação Corporal Total , Zinostatina/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA